

related to the risk of hospitalization in patients with schizophrenia. However, there are no studies describing which clinical factors increase the likelihood of being hospitalized while undergoing home follow-up.

Objectives: To determine which of the clinical factors assessed in the PANSS predict the risk of hospitalization in patients diagnosed with schizophrenia following a home treatment program.

Methods: All patients with schizophrenia who were visited by a home treatment team in Barcelona between January 2017 and December 2021 were included in the study. A comparative, bivariate analysis of each item of the PANSS and of the global results of each category was conducted on those who were hospitalized and those who were not hospitalized. Finally, a logistic regression of each category of the PANSS was done on both groups, controlling for other socio-demographic and clinical factors.

Results: A total of 1045 patients with schizophrenia were evaluated in this study. PANSS positive symptom subscale (PANSS-S), PANSS General Psychopathology, PANSS Excited Component and PANSS Global Score scored higher in patients who were finally hospitalized in a conventional acute treatment unit. Regarding the PANSS negative symptom subscale, no significant differences were found between the two groups.

In patients who required hospitalization, the scores of all the PANSS positive symptom subscale (PANSS-P) items and all items on the PANSS excited component (excitement, tension, hostility, uncooperativeness and poor impulse control) were significantly higher. Some items regarding general psychopathology (Somatic concern, anxiety, guilt feelings, tension, and mannerisms) were also significantly higher in the hospitalization group. Only 3 items—blunted affect, guilt feelings and motor retardation—scored significantly higher in patients who did not require hospitalization. In the logistic regression, only the global score of the PANSS-P reached statistical significance ($P = 0.001$).

Conclusions: Positive symptoms scored in the PANSS seem to be the most predictive factors of hospitalization regarding clinical symptoms in patients with Schizophrenia following home treatment. Other items regarding exciting symptoms and general psychopathology also showed as relevant regarding the risk of conventional hospitalization in those patients.

Disclosure of Interest: None Declared

EPP1059

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence

E. Rancans¹, Z. B. Dombi², R. Csehi^{2*} and G. Németh²

¹Department of Psychiatry and Narcology, Riga Stradins University, Riga, Latvia and ²Gedeon Richter Plc., Budapest, Hungary

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1333

Introduction: There is an increasing need to understand the effectiveness of novel medications in real-world context since despite being the gold standard, double-blind trials have their own limitations as well. Clinical Global Impression is a simple tool for clinicians to assess the severity of an illness (CGI-Severity) as well as to rate how much the patient's disorder has improved or worsened

relative to baseline (CGI-Improvement). In this poster, cariprazine, a third-generation antipsychotic medication that was found to be effective in the treatment of negative symptoms in schizophrenia will be evaluated.

Objectives: To compare the effectiveness of cariprazine in clinical trial vs real-world setting via the CGI-S and CGI-I scales in negative symptom schizophrenia patients.

Methods: We compared the results of a clinical trial (Németh et al. Lancet 2017; 389:1103-13) and an observational study (Rancans et al. Int Clin Psychopharmacol. 2021;36(3):154-161). The latter was an open-label, flexible-dose, 16-week, observational study of cariprazine involving 116 outpatients in Latvia. Adult patients who have been diagnosed with schizophrenia, exhibited negative symptoms based on clinical judgement, were at least mildly ill according to the CGI-S scale and have not previously received cariprazine were eligible to take part in the study. Dosing of cariprazine was based on clinical judgement. The clinical trial was a randomized, double-blind, multi-centred, 26-week study with adults aged 18–65 years with long-term (>2 year), stable schizophrenia and predominant negative symptoms (>6 months). Patients were randomly assigned to monotherapy with cariprazine 4.5 mg/day or risperidone 4.0 mg/day.

Results: 116 patients on flexible dose cariprazine (observational study) were compared with 227 patients on cariprazine 4.5 mg/day and 229 on risperidone 4.0 mg/day (clinical trial). Baseline severity of illness as measured by the CGI-S was between moderately and markedly ill in all three groups. By the end of the 26-week trial, cariprazine reduced the CGI-S score significantly (LS Mean Change: -0.9, $p < 0.01$). In contrast, the risperidone group achieved only -0.7-point change from baseline. In the observational study, cariprazine also achieved significant change (-0.9, $p < 0.001$) but by week 16. In terms of improvement, patients on cariprazine improved minimally to much in both the clinical trial and real-world setting.

Conclusions: The effectiveness of cariprazine in clinical trial and real-world setting do not seem to differ as measured by the scales in negative symptom patients.

Disclosure of Interest: E. Rancans Grant / Research support from: Gedeon Richter, Lundbeck, Consultant of: Abbvie, Gedeon Richter, Grindex, Janssen Cilag, Lundbeck, Servier, Zentiva, Speakers bureau of: Abbvie, Gedeon Richter, Grindex, Janssen Cilag, Lundbeck, Servier, Zentiva, Z. Dombi Employee of: Gedeon Richter Plc., R. Csehi Employee of: Gedeon Richter Plc., G. Németh Employee of: Gedeon Richter Plc.

EPP1060

Relationship between CAINS negative symptoms and cognition, psychosocial functioning and quality of life in patients with a first psychotic episode of schizophrenia

R. Rodríguez-Jiménez^{1,2,3*}, L. García-Fernández^{3,4}, V. Romero-Ferreiro^{3,5}, M. Valtueña García¹, A. I. Aparicio^{3,6}, J. M. Espejo-Saavedra¹, L. Sánchez-Pastor¹, A. Nuñez-Doyle¹, M. Dompablo^{1,3}, O. Jiménez-Rodríguez¹, D. Rentero¹, P. Fernández-Sotos^{3,7}, I. Martínez-Gras¹ and J. L. Santos^{3,6}

¹Psychiatry, Hospital Universitario 12 de Octubre; ²Psychiatry, Universidad Complutense de Madrid; ³CIBERSAM, Madrid;

⁴Psychiatry, Univesidad Miguel Hernandez, Alicante; ⁵Quality and Academic Compliance Unit, Universidad Europea de Madrid,

Madrid; ⁶Psychiatry, Hospital Virgen de la Luz, Cuenca and ⁷Salud Mental, Complejo Hospitalario Universitario de Albacete, Albacete, Spain

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1334

Introduction: Negative symptoms has been classically associated with cognition, psychosocial functioning and quality of life in patients with schizophrenia. But negative symptoms are not a unitary construct, encompassing two different factors: diminished expression, and motivation and pleasure. Few works have studied the relationship between these two different negative symptoms factors and cognition (neuro and social cognition), psychosocial functioning and quality of life, jointly, in patients with a first psychotic episode of schizophrenia.

Objectives: The objective of the present work was to study, in a sample of patients with a first psychotic episode of schizophrenia, the relationship between the negative symptoms (diminished expression and motivation and pleasure) and neurocognition, social cognition, functioning and quality of life.

Methods: The study was carried out with 82 outpatients with a first psychotic episode of schizophrenia from two Spanish hospitals ("12 de Octubre" University Hospital, Madrid and "Virgen de la Luz" Hospital, Cuenca). The patients were assessed with the Clinical Assessment Interview for Negative Symptoms (CAINS) for evaluating diminished expression (EXP) and motivation and pleasure (MAP) symptoms, the MATRICS Consensus Cognitive Battery (MCCB) for evaluating neurocognition and social cognition, the Social and Occupational Functioning Assessment Scale (SOFAS), and the Quality of Life Scale (QLS).

Results: A negative correlation was found between neurocognition and the two negative symptoms subscales: CAINS-EXP ($r=-0.458$, $p<0.001$) and CAINS-MAP ($r=-0.374$, $p<0.001$); but with social cognition only CAINS-EXP was correlated ($r=-0.236$, $p=0.033$). Also, it was found a high negative correlation between SOFAS scores and CAINS-MAP ($r=-0.717$, $p<0.001$); and a medium negative correlation with CAINS-EXP ($r=-0.394$, $p<0.001$). Finally, QLS score was high correlated with both CAINS subscales: CAINS-EXP ($r=-0.681$, $p<0.001$) and CAINS-MAP ($r=-0.770$, $p<0.001$).

Conclusions: This study found a relationship between negative symptoms and neurocognition, social cognition, functioning and quality of life in a sample of patients with a first psychotic episode of schizophrenia. But the two different negative symptom factors, diminished expression, and motivation and pleasure, are associated differently with psychosocial functioning, but especially with social cognition where the relationship was only found with diminished expression symptoms.

Disclosure of Interest: None Declared

EPP1061

Switching Antipsychotic Medications in People with Schizophrenia: A 4-Year Naturalistic Study

R. Ceres^{1*}, M. Battipaglia¹, S. Donato¹, N. Attianese¹, G. M. Giordano¹, P. Bucci¹ and G. Cascino²

¹University of Campania Luigi Vanvitelli, Naples and ²University of Salerno, Scuola Medica Salernitana, Salerno, Italy

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1335

Introduction: Although generally effective in ameliorating the core manifestations of schizophrenia, antipsychotics (APs) may lead to only suboptimal responses or may be associated with a variety of treatment-related adverse events which require additional treatment strategies. Under such clinical circumstances, switching APs represents a rational treatment option.

Objectives: The present study aimed to identify the variables that predict AP switch and to quantify the frequency of this phenomenon in people with schizophrenia in real-life.

Methods: A secondary analysis was conducted on the data collected at baseline and at a 4-year follow-up from a large sample of community-dwelling Italian people with schizophrenia. Demographic and clinical variables as well as information about AP treatment were recorded at two time points. Over the 4-year period, 34.9% of the 571 participants switched the AP; in particular, 8.4% of participants switched from first-generation APs (FGAs) to second-generation APs or vice versa, while 8.2% of them switched to clozapine.

Results: Logistic regression models showed that combination of APs at baseline was negatively associated with AP switch, while treatment with FGAs and the presence of extrapyramidal symptoms at baseline were associated with AP class switch.

Conclusions: Although the aim of the present study was not to assess predictors of clinical relapse in people with schizophrenia, we might speculate that switching APs represents a surrogate indicator of treatment failure in some patients and could lead into relapse, which is a costly aspect of schizophrenia management in both economic and human terms. The sooner such a negative outcome can be predicted and managed, the sooner the treatment can be optimized to avoid it.

Disclosure of Interest: None Declared

Sexual Medicine and Mental Health

EPP1062

Temperament and Character among mothers of individuals with gender dysphoria: a case-control study

A. Talaei*, S. Omidvar Tehrani and Z. Talaei

¹Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, Islamic Republic Of

*Corresponding author.

doi: 10.1192/j.eurpsy.2023.1336

Introduction: Parents of individuals with gender dysphoria may experience distress when dealing with their child's condition, and how they react can have a significant effect on their own as well as their child's mental health.

Objectives: In this study, we aimed to explore the personality traits among mothers of individuals with gender dysphoria in comparison to the mothers of individuals with cis-gender identity by utilizing the Temperament and Character Inventory (TCI) tool.

Methods: We enrolled 27 mothers of GD individuals who had obtained licenses for gender affirmation surgery and 28 mothers of cisgender controls for this case-control study. Personality traits were measured by a validated Farsi version of the Temperament and Character Inventory (TCI) tool.